168 related articles for article (PubMed ID: 34170361)
1.
Liu T; Liu C; Zhang Z; Zhang N; Guo X; Xia L; Jiang J; Xie Q; Yan K; Rowe SP; Zhu H; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4508-4516. PubMed ID: 34170361
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation and Pilot Clinical Study of Al
Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
5. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, preclinical evaluation, and first-in-human study of Al
Wu Y; Zhang X; Zhou H; Xu B; Tian J; Sun S; Zhang J
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2774-2785. PubMed ID: 35396969
[TBL] [Abstract][Full Text] [Related]
7. The Feasibility of
Lee CH; Lim I; Woo SK; Kim KI; Lee KC; Song K; Choi CW; Lim SM
Cancer Biother Radiopharm; 2022 Aug; 37(6):417-423. PubMed ID: 33434438
[No Abstract] [Full Text] [Related]
8. [
Rosar F; Schaefer-Schuler A; Bartholomä M; Maus S; Petto S; Burgard C; Privé BM; Franssen GM; Derks YHW; Nagarajah J; Khreish F; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4736-4747. PubMed ID: 35930033
[TBL] [Abstract][Full Text] [Related]
9. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H
Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629
[TBL] [Abstract][Full Text] [Related]
10. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
Nedrow JR; Latoche JD; Day KE; Modi J; Ganguly T; Zeng D; Kurland BF; Berkman CE; Anderson CJ
Mol Imaging Biol; 2016 Jun; 18(3):402-10. PubMed ID: 26552656
[TBL] [Abstract][Full Text] [Related]
11. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
12. [
Green MA; Hutchins GD; Bahler CD; Tann M; Mathias CJ; Territo W; Sims J; Polson H; Alexoff D; Eckelman WC; Kung HF; Fletcher JW
Mol Imaging Biol; 2020 Jun; 22(3):752-763. PubMed ID: 31429050
[TBL] [Abstract][Full Text] [Related]
13. Phase I Study of CTT1057, an
Behr SC; Aggarwal R; VanBrocklin HF; Flavell RR; Gao K; Small EJ; Blecha J; Jivan S; Hope TA; Simko JP; Kurhanewicz J; Noworolski SM; Korn NJ; De Los Santos R; Cooperberg MR; Carroll PR; Nguyen HG; Greene KL; Langton-Webster B; Berkman CE; Seo Y
J Nucl Med; 2019 Jul; 60(7):910-916. PubMed ID: 30464040
[TBL] [Abstract][Full Text] [Related]
14. Application of Cu-64 NODAGA-PSMA PET in Prostate Cancer.
Sevcenco S; Klingler HC; Eredics K; Friedl A; Schneeweiss J; Knoll P; Kunit T; Lusuardi L; Mirzaei S
Adv Ther; 2018 Jun; 35(6):779-784. PubMed ID: 29777523
[TBL] [Abstract][Full Text] [Related]
15. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution and radiation dosimetry of [
Hohberg M; Kobe C; Krapf P; Täger P; Hammes J; Dietlein F; Zlatopolskiy BD; Endepols H; Wild M; Neubauer S; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
EJNMMI Res; 2019 Jul; 9(1):66. PubMed ID: 31346821
[TBL] [Abstract][Full Text] [Related]
17. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
[No Abstract] [Full Text] [Related]
18. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.
Pfob CH; Ziegler S; Graner FP; Köhner M; Schachoff S; Blechert B; Wester HJ; Scheidhauer K; Schwaiger M; Maurer T; Eiber M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1962-70. PubMed ID: 27207281
[TBL] [Abstract][Full Text] [Related]
19. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.
Afshar-Oromieh A; Hetzheim H; Kübler W; Kratochwil C; Giesel FL; Hope TA; Eder M; Eisenhut M; Kopka K; Haberkorn U
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1611-20. PubMed ID: 27260521
[TBL] [Abstract][Full Text] [Related]
20. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
